Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5209452
Max Phase: Preclinical
Molecular Formula: C23H19N3O
Molecular Weight: 353.43
Associated Items:
ID: ALA5209452
Max Phase: Preclinical
Molecular Formula: C23H19N3O
Molecular Weight: 353.43
Associated Items:
Canonical SMILES: COc1cccc(Cn2ccc3cc(-c4cnc5[nH]ccc5c4)ccc32)c1
Standard InChI: InChI=1S/C23H19N3O/c1-27-21-4-2-3-16(11-21)15-26-10-8-18-12-17(5-6-22(18)26)20-13-19-7-9-24-23(19)25-14-20/h2-14H,15H2,1H3,(H,24,25)
Standard InChI Key: LQYYCWAMFYGKEB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 353.43 | Molecular Weight (Monoisotopic): 353.1528 | AlogP: 5.24 | #Rotatable Bonds: 4 |
Polar Surface Area: 42.84 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 3.13 | CX LogP: 4.76 | CX LogD: 4.76 |
Aromatic Rings: 5 | Heavy Atoms: 27 | QED Weighted: 0.48 | Np Likeness Score: -1.08 |
1. Li Y, Zhang L, Yang R, Qiao Z, Wu M, Huang C, Tian C, Luo X, Yang W, Zhang Y, Li L, Yang S.. (2022) Discovery of 3,4-Dihydrobenzo[f][1,4]oxazepin-5(2H)-one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects., 65 (3.0): [PMID:34985886] [10.1021/acs.jmedchem.1c00672] |
Source(1):